Neuromyelitis Optica: Clinical Trials

32 trials for Neuromyelitis Optica, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 7 recruiting, 4 not yet recruiting, 2 unknown. 32 Phase 1, 12 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 132Completed 15, Recruiting 7, Not yet recruiting 4, Unknown 2, Withdrawn 2, Active not recruiting 1, Terminated 1
Phase 212Completed 5, Not yet recruiting 2, Recruiting 2, Unknown 2, Terminated 1

Follow Neuromyelitis Optica: new trials by email Literature Review of Neuromyelitis Optica trials Research Report on Neuromyelitis Optica

Trials (filtered) newest first · largest first

All 32 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder
Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder
Phase 1 / Phase 2Not yet recruitingTianjin Medical University General Hospital202026-12-012026-10-16
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
CTX112 - Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica
Phase 1 / Phase 2Not yet recruitingCRISPR Therapeutics2202026-11-012026-10-22
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG)
Phase 1Not yet recruitingThe Affiliated Hospital of Qingdao University182026-07-012026-06-30
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 1RecruitingTongji Hospital62026-04-012026-05-12
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
CD20/BCMA-directed CAR-T cells - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD)
Phase 1Not yet recruitingHuashan Hospital152026-02-012026-01-15
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Azercabtagene zapreleucel (azer-cel) - B-cell Mediated Autoimmune Disorders
Phase 1RecruitingTG Therapeutics, Inc.1002025-05-062026-10-27
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
BAFF-R CART - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder
Phase 1 / Phase 2RecruitingTianjin Medical University General Hospital272025-04-102026-10-16
The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection, A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection - Neuromyelitis Optica Spectrum Disorders
Phase 1RecruitingTongji Hospital692025-03-282026-09-21
A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients
IMC-002, mycophenolate mofetil, MMF - Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 1 / Phase 2UnknownImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.1162024-10-102024-08-16
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
HBI0101 CART - Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
Phase 1RecruitingPolina Stepensky1202024-09-012026-05-06
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
CD20/BCMA-directed CAR-T cells - Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM)
Phase 1RecruitingRenJi Hospital302024-03-202025-07-25
Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica
CAR-T cells injection - Neuromyelitis Optica
Phase 1CompletedZhejiang University92023-05-152025-08-11
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
Baricitinib - NMO Spectrum Disorder
Phase 1Active not recruitingTianjin Medical University General Hospital112023-04-152026-08-11
Ofatumumab in AQP4-IgG Seropositive NMOSD
Ofatumumab - Neuromyelitis Optica Spectrum Disorder
Phase 1 / Phase 2RecruitingTang-Du Hospital52022-06-282026-01-30
A Study of LP-168 in Healthy Volunteers
LP-168 tablet, LP-168 Placebo tablet - Multiple Sclerosis, NMO Spectrum Disorder
Phase 1CompletedGuangzhou Lupeng Pharmaceutical Company LTD.702022-05-142023-02-24
Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders
Belimumab - NMO Spectrum Disorder
Phase 1 / Phase 2CompletedTianjin Medical University General Hospital142021-12-122024-10-16
A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
BAT4406F - Neuromyelitis Optica Spectrum Disorders
Phase 1CompletedBio-Thera Solutions152020-09-012025-07-10
A Study of HBM9161 in NMOSD Patients
HBM9161 Injection - NMO Spectrum Disorder
Phase 1CompletedHarbour BioMed (Guangzhou) Co. Ltd.92020-03-312022-01-25
Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20
Corticosteroids & tanCART19/20 - Neuromyelitis Optica Spectrum Disorder
Phase 1WithdrawnChinese PLA General Hospital2018-08-152019-09-19
Central Pain Study for ABX-1431
ABX-1431 HCl, Placebo - Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis
Phase 1CompletedAbide Therapeutics92017-08-012019-01-25

Showing 20 of 32. Sign in to see all of them.

Narrower conditions

Multiple Sclerosis (9)  ·  Myasthenia Gravis (6)  ·  Autoimmune Diseases of the Nervous System (3)  ·  Lupus Erythematosus, Systemic (3)  ·  Multiple Sclerosis, Chronic Progressive (3)  ·  Myelitis, Transverse (3)  ·  Myositis (3)  ·  Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (3)  ·  Scleroderma, Systemic (3)  ·  Optic Neuritis (2)  ·  Stiff-Person Syndrome (2)  ·  Antiphospholipid Syndrome (1)  ·  Arthritis, Rheumatoid (1)  ·  Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (1)

Broader conditions

Autoimmune Diseases (32)  ·  Cranial Nerve Diseases (32)  ·  Demyelinating Autoimmune Diseases, CNS (32)  ·  Demyelinating Diseases (32)  ·  Eye Diseases (32)  ·  Immune System Diseases (32)  ·  Nervous System Diseases (32)  ·  Optic Nerve Diseases (32)  ·  Optic Neuritis (30)  ·  Autoimmune Diseases of the Nervous System (29)  ·  Myelitis, Transverse (29)  ·  Neoplasms (9)  ·  Neoplasms by Site (9)  ·  Nervous System Neoplasms (9)  ·  Neurodegenerative Diseases (9)

Interventions

Cyclophosphamide (2)  ·  Methylprednisolone (2)  ·  Methylprednisolone Hemisuccinate (2)  ·  Rituximab (2)  ·  Adrenal Cortex Hormones (1)  ·  Antilymphocyte Serum (1)  ·  Bevacizumab (1)  ·  Cetirizine (1)  ·  Complement C1 Inhibitor Protein (1)  ·  Filgrastim (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  HBM9161 (1)  ·  Hematopoietic Stem Cell Transplantation (1)  ·  Immunotherapy, Adoptive (1)  ·  Injections, Spinal (1)

Sponsors

Tianjin Medical University General Hospital (4)  ·  Johns Hopkins University (2)  ·  Tongji Hospital (2)  ·  Abide Therapeutics (1)  ·  Bio-Thera Solutions (1)  ·  CRISPR Therapeutics (1)  ·  Chinese PLA General Hospital (1)  ·  Fu-Dong Shi (1)  ·  Guangzhou Lupeng Pharmaceutical Company LTD. (1)  ·  Harbour BioMed (Guangzhou) Co. Ltd. (1)  ·  Huashan Hospital (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. (1)  ·  Mayo Clinic (1)  ·  Michael Levy (1)

Countries

China (15)  ·  United States (9)  ·  Canada (1)  ·  Israel (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Michael Levy, MD, PhD (3)  ·  Alexandra L Goodyear, MD, MS (1)  ·  Anu Jacob, MD DM FRCP (1)  ·  Bruce Cree, MD, PhD (1)  ·  Chuan Qin (1)  ·  Chuan Qin, MD (1)  ·  Dai-shi Tian, MD (1)  ·  Daishi Tian (1)  ·  Fu-Dong Shi, MD,PhD (1)  ·  He Huang, MD (1)  ·  Huanfen Zhou, PhD (1)  ·  Ilana Katz Sand, MD (1)  ·  Jacqueline Palace, FRCP DM (1)  ·  Jan Storek, MD,PhD (1)  ·  Jing Zhang (1)

Results publications

PMID 23623397, PMID 25191939, PMID 39592888, PMID 40489809